“The recent months have been productive for our company,” said Maria Maccecchini, Ph.D., Founder, President, and CEO of Annovis Bio. “We’ve completed pivotal Phase 2/3 Alzheimer’s and Phase 3 Parkinson’s studies, both of which revealed very encouraging data for buntanetap. Additionally, we’ve introduced a new crystalline form of buntanetap with improved properties, further strengthening our IP portfolio. These milestones position us strongly as we move closer to providing much-needed treatments to patients.”
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ANVS:
- Largest borrow rate increases among liquid names
- Annovis Bio initiated with a Buy at EF Hutton
- Annovis Bio announces preclinical data on buntanetap with GLP-1 agonist
- Annovis’ Lead Compound Enhances Cognition Synergistically with GLP-1 Agonist
- Annovis Bio secures U.S. patent for treatment of acute TBI with buntanetap